Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
experimental medication |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
1048983-02-2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Roche
|
| gptkbp:hasMolecularFormula |
C19H18F3N3O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
basimglurant
|
| gptkbp:intendedUse |
treatment of fragile X syndrome
|
| gptkbp:mechanismOfAction |
mGlu5 receptor negative allosteric modulator
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103886
25154816 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:synonym |
RG7090
RO4917523 |
| gptkbp:UNII |
6Q1K1VJ0ZC
|
| gptkbp:bfsParent |
gptkb:STX-101
|
| gptkbp:bfsLayer |
8
|